The Rush Hemophilia & Thrombophilia Center (RHTC) at the Rush University Medical Center in Chicago, IL, has been awarded the first grant through the Octapharma 25th Anniversary Grants Program. The program supports clinical or pre-clinical research on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.
The lead investigator for the research project is Leonard A. Valentino, MD, director of the section of pediatric hematology-oncology at RHTC. Valentino, a physician with nearly 20 years experience with bleeding and clotting disorders, will study the impact of age at the time of first hemarthrosis (joint bleed) on the development of arthropathy (joint damage). Valentino leads one of the largest pediatric hemophilia and thrombophilia centers in the U.S. and an active basic and translational science research group. His research focus has been on the causes and mechanisms of blood-induced joint disease.
“It is an honor for Octapharma to support the valuable research being pursued by the Rush Hemophilia & Thrombophilia Center,” said Flemming Nielsen, President, Octapharma USA. “Dr. Valentino is a well-recognized national leader in the field of pediatric hematology and oncology and we consider his research extremely important. The grant continues to advance our firm commitment to the U.S. market of ensuring that patients receive the safest, highest quality therapies available today.”
Source: PR Newswire, August 2, 2010
